EMAIL THIS PAGE TO A FRIEND

Leukemia

Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling.


PMID 24727677

Abstract

The t(8;21)(q22;q22) rearrangement represents the most common chromosomal translocation in acute myeloid leukemia (AML). It results in a transcript encoding for the fusion protein AML1-ETO (AE) with transcription factor activity. AE is considered to be an attractive target for treating t(8;21) leukemia. However, AE expression alone is insufficient to cause transformation, and thus the potential of such therapy remains unclear. Several genes are deregulated in AML cells, including KIT that encodes a tyrosine kinase receptor. Here, we show that AML cells transduced with short hairpin RNA vector targeting AE mRNAs have a dramatic decrease in growth rate that is caused by induction of apoptosis and deregulation of the cell cycle. A reduction in KIT mRNA levels was also observed in AE-silenced cells, but silencing KIT expression reduced cell growth but did not induce apoptosis. Transcription profiling of cells that escape cell death revealed activation of a number of signaling pathways involved in cell survival and proliferation. In particular, we find that the extracellular signal-regulated kinase 2 (ERK2; also known as mitogen-activated protein kinase 1 (MAPK1)) protein could mediate activation of 23 out of 29 (79%) of these upregulated pathways and thus may be regarded as the key player in establishing the t(8;21)-positive leukemic cells resistant to AE suppression.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300489
Anti-KIT (Ab-721) antibody produced in rabbit, affinity isolated antibody
SAB4300593
Anti-KIT (Ab-936) antibody produced in rabbit, affinity isolated antibody
GW21114 Anti-KIT antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1412042
ANTI-KIT antibody produced in mouse, clone 1G1, purified immunoglobulin, buffered aqueous solution
SAB1412043
ANTI-KIT antibody produced in mouse, clone 5F6, purified immunoglobulin, buffered aqueous solution
SAB1412044
ANTI-KIT antibody produced in mouse, clone 5A11, purified immunoglobulin, buffered aqueous solution
SAB1412045
ANTI-KIT antibody produced in mouse, clone 2C3, purified immunoglobulin, buffered aqueous solution
SAB1412046
ANTI-KIT antibody produced in mouse, clone 1D3, purified immunoglobulin, buffered aqueous solution
SAB1412140
ANTI-KIT antibody produced in mouse, clone 4F7, purified immunoglobulin, buffered aqueous solution
SAB1412141
ANTI-KIT antibody produced in mouse, clone 3A8, purified immunoglobulin, buffered aqueous solution
HPA004471
Anti-KIT antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4700750
Monoclonal Anti-CD117 antibody produced in mouse, clone 104D2, purified immunoglobulin, buffered aqueous solution
WH0003815M2
Monoclonal Anti-KIT antibody produced in mouse, clone 6F2, purified immunoglobulin, buffered aqueous solution
AMAB90901
Monoclonal Anti-KIT antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1657, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90904
Monoclonal Anti-KIT antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1667, purified immunoglobulin, buffered aqueous glycerol solution
SAB1404007
Monoclonal Anti-KIT antibody produced in mouse, clone 6G12, purified immunoglobulin, buffered aqueous solution
SAB5300439
Monoclonal Anti-KIT antibody produced in mouse, clone 8D7, ascites fluid
SAB5300440
Monoclonal Anti-KIT antibody produced in mouse, clone 1C5, ascites fluid